arrow
Y

Yanhong Gu

Nanjing Medical University
H指数:37
被引数:4,409

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials

Glecirasib联合或不联合西妥昔单抗治疗既往经治的局部晚期或转移性KRASG12C突变结直肠癌(JAB-21822-1002和JAB-21822-1007):两项开放标签、非随机化I/II期临床试验

2025-12-010
PRE
Correction to “Proteomic Profiling of Urinary Large Extracellular Vesicles for the Diagnosis of Prostate Cancer”

对“Proteomic Profiling of Urinary Large Extracellular Vesicles for the Diagnosis of Prostate Cancer”的更正

2025-10-040
OAAI
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

glecirasib在KRAS G12C突变实体瘤中的有效性和安全性:两项I/II期试验的合并分析

2025-10-020
OAAI
Proteomic Profiling of Urinary Large Extracellular Vesicles for the Diagnosis of Prostate Cancer

尿液中大囊泡的蛋白质组学分析及其在前列腺癌诊断中的应用

2025-07-160
PRE
PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial

PD-1抗体camrelizumab联合apatinib和SOX作为AFP产生性胃或胃食管结合部腺癌患者的一线治疗(CAP 06):一项多中心、单臂、II期临床试验

2025-03-140
OA
Efficacy and safety of Xian-Lian-Jie-Du optimization decoction as an adjuvant treatment for prevention of recurrence in patients with stage IIIB/IIIC colon cancer: study protocol for a multicentre, randomized controlled trial
2023-07-175
OAAI
China special issue on gastrointestinal tumor-improved survival after multidisciplinary team decision for patients with advanced gastrointestinal cancer: A multicenter, noninterventional, controlled study

中国胃肠道肿瘤特刊 -- 晚期胃肠道肿瘤患者多学科团队决策后生存改善: 一项多中心、非干预性对照研究

2023-06-097
OAAI
High Throughput Isolation and Data Independent Acquisition Mass Spectrometry (DIA-MS) of Urinary Extracellular Vesicles to Improve Prostate Cancer Diagnosis

尿细胞外囊泡高通量隔离和数据独立采集质谱 (DIA-MS) 提高前列腺癌诊断

2022-11-2310
OAAI